SODIUM CHLORIDE , RITUXIMAB, MYCOPHENOLIC ACID
DR230333
Phase 3 small_molecule active
Quick answer
SODIUM CHLORIDE , RITUXIMAB, MYCOPHENOLIC ACID for Intersitial lung disease related to systemic sclerosis is a Phase 3 program (small_molecule) at Tour Hekla with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tour Hekla
- Indication
- Intersitial lung disease related to systemic sclerosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active